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Abstract
Amajor challenge in the field of ligand discovery is to identify chemically useful fragments
that can be developed into inhibitors of specific protein-protein interactions. Low molecular
weight fragments (with molecular weight less than 250 Da) are likely to bind weakly to a pro-
tein’s surface. Here we use a new virtual screening procedure which uses a combination of
similarity searching and docking to identify chemically tractable scaffolds that bind to the
p53-interaction site of MDM2. The binding has been verified using capillary electrophoresis
which has proven to be an excellent screening method for such small, weakly binding
ligands.
Introduction
Virtual screening (VS) to identify ligands that will interrupt protein-protein interactions re-
mains challenging [1–3]. There are now a large number of VS success stories present in the lit-
erature, with targets as diverse as G-protein coupled receptors [4], enzymes such as
angiotensin converting enzyme [5], zinc β-lactamase [6] and monoamine oxidase A [7], and
Tat-TAR RNA Interactions [8] successfully targeted. However, most conventional VS ap-
proaches identify large hydrophobic molecules less suited to chemical modification; indeed it
has been shown that docking programs tend to be biased in favour of larger molecules [9]. In
addition, docking programs also struggle to accurately predict the binding modes of small frag-
ment-like molecules [10]. Testing the predicted hits is also problematic for weak binding li-
gands, though SPR, NMR and ITC can be used if the ligands are sufficiently soluble. In this
work we show capillary electrophoresis (CE) is a powerful technique with a number of
advantages.
The target for this work is the p53 binding pocket of MDM2. The tumour suppressor p53
regulates the cell cycle through arresting growth and causing apoptosis in damaged or aberrant
cells [11]. In unstressed cells, p53 is held at low levels to allow normal functions such as mitosis
to continue. The E3 ligase MDM2 suppresses the activity of p53 via polyubiquitination and
subsequent degradation by the proteasome [12–16]. Cancer cells have been shown to be
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particularly sensitive to restoration of p53 function, suggesting that inhibition of downregula-
tors of its function should be a viable approach for the development of anticancer therapies
[17–29].
There are several different classes of small molecule inhibitors of MDM2 that are able to in-
terfere with MDM2-p53 binding with potency in the nM range (see Fig 1 for details of a selec-
tion of these). One such molecule, named reactivation of p53 and induction of tumour cell
apoptosis (RITA), has been shown to induce apoptosis in some cancer cell lines [30–32], al-
though it may not be a classical MDM2-p53 interaction disruptor [33]. A second class of small
Fig 1. Crystal structures of MDM2with bound small molecules.
doi:10.1371/journal.pone.0121424.g001
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molecules, the Nutlins, are high affinity inhibitors of MDM2 and induce activation of p53 by
binding to the p53 binding pocket of MDM2 [34]. Spiro-oxindoles comprise a third class [25,
26, 35, 36]. In this work we identified a number of lead-like compounds, which led to the dis-
covery of several fragments that provide new chemical scaffolds that could serve as the core of
novel MDM2 inhibitor families.
Materials and Methods
Docking parameters and Control Experiments
Water molecules and other hetero atoms were removed from the structures and the program
PDB2PQR 1.8 [37] was used to assign position-optimised hydrogen atoms, utilising the addi-
tional PropKa [38] algorithm with a pH of 7.4 to predict protonation states. The MGLTools
1.5.4 utility prepare_receptor4.py was used to assign Gasteiger charges to atoms. Hydrogen
atoms were assigned to ligand structures using OpenBabel 2.3.1 [39], utilising the-p option to
predict the protonation states of functional groups at pH 7.4. The MGLTools utility prepare_li-
gand4.py was used to assign Gasteiger charges and rotatable bonds. As Vina 1.1.2 [40] and
Autodock 4.2.3 [41–43] both use the same. pdbqt format for their input, the same prepared
files could be used for each. A grid box that encompassed the maximum dimensions of the li-
gand plus 12 Å in each direction was used. The starting translation and orientation of the li-
gand and the torsion angles of all rotatable bonds were set to random. The Autogrid grid point
spacing was set at 0.2 Å. The Autodock parameter file specified 10 Lamarckian genetic algo-
rithm runs, 2,000,000 energy evaluations and a population size of 300. Each docking program
was used to automatically dock the ligand back into the p53 binding pocket of MDM2.
Curation of the Virtual Chemical Library
The screening compound stock lists in SDF format of ChemBridge, Asinex, Maybridge, En-
amine, LifeChemicals, Specs, InterBioScreen, ChemDiv and KeyOrganics were merged. Salts
were stripped out using Sieve 3.1.0 [44], and duplicates removed using canonical SMILES
string comparison via Open Babel 2.3.1. The supplied 2D coordinates were converted into 3D
using Concord 4.08 [45]. Because the aim was to identify initial lead-like hits suitable for opti-
misation into more drug-like molecules, the virtual library was filtered according to Oprea
"lead-like" rules (H-bond acceptors 9; H-bond donors 5; MW460; cLogP -4.6 4.2;
cLogS -5; Number of rings 4; Number of rotatable bonds 9) [46]. This left 1,137,587
molecules. A multi-conformer version of this virtual library was produced using Multiconf-
DOCK [47]; an average of 4.25 conformers per compound were generated depending on flexi-
bility; this resulted in a virtual library containing a total of 4,840,093 conformers.
Virtual Screening
An initial ligand-based pharmacophore screen was carried out. All ligands (both peptides and
small molecules) present in the p53 binding pocket of MDM2 in all of the crystal structures in
the PDB were used as search terms (S1 Table). The programs UFSRAT [48], ROCS [49] and a
Wiener index similarity comparison algorithm available as part of EDULISS [50] were used to
search the virtual library for molecules with different types of similarity to the known ligands.
Specifically, UFSRAT (Ultra Fast Shape Recognition with Atom Types) is a shape recognition
algorithm that takes into account atom types, which places importance not only on the space-
filling properties of a small molecule, but also possible electrostatic interactions. An expansion
of the validated [51] USR technique, the UFSRAT similarity calculation process consists of
three steps: first, shape and atom property descriptors are calculated for each molecule; second,
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the descriptors are compared using a scoring function, and finally, similar molecules are ranked
by score. The UFSRAT search of the multiconformer library returned 9,999 molecules.
ROCS (Rapid Overlay of Chemical Structures) is also a shape matching algorithm but uses a
smooth Gaussian function to represent the molecular volume, analytically optimizing the vol-
ume intersection of the two molecules being compared [52]. The shape comparison method
uses “shape multipoles” that can be used to describe the inherent shape of molecules. This is
coupled with chemistry matching based on a user-definable chemical force-field. The ROCS
search of the multiconformer library returned 10,021 molecules.
Wiener index comparison is a well-known and long-established method in chemical graph
theory that can be used to measure molecular similarity [53]. A type of molecular descriptor,
the Wiener index (also known as Wiener number) is a topological index of a molecule, defined
as the sum of the lengths of the shortest paths between all pairs of vertices in the chemical
graph representing the non-hydrogen atoms in the molecule [54]. The calculation of this index
by EDULISS 2.0 deduces the path number and the polarity number of a compound. The polari-
ty number is defined as the number of pairs of atoms which are separated by three bonds. The
query and library compound comparison is based on Euclidean distance, i.e. the shorter the
distance between the indices of query and library molecule, the more the connectivity of their
bonds is similar. The EDULISS search returned 4,545 molecules.
In addition, the rigid-body docking program LIDAEUS [55] was used to dock the conform-
er virtual library into the p53 binding site of the MDM2 crystal structure. The results were
ranked according to LIDAEUS score, the top 65,906 compounds from this list merged with the
results from the ligand-based methods described above, and the duplicates removed. This re-
sulted in 79,611 unique molecules which were then docked into MDM2 using Vina. Docked
poses were scored using both Vina’s internal scoring algorithm and X-Score 1.2 [56]; these
scores were used via a “rank-by-rank” consensus scheme [57] to create a ranked list. The top
4,469 compounds were then docked using Autodock. Predicted binding poses were also scored
using DrugScore 1.2 [58]. The addition of DrugScore and X-Score to the scoring scheme was
prompted by the results of several groups which have shown that these programs are among
the most accurate in predicting affinity [59, 60], and that the use of several scoring algorithms
in a "consensus scoring" scheme generally produces better results, both in virtual screening
arena [10, 59–65] and in related fields [66–68]. Indeed, information fusion has been shown to
improve performance in a broad range of human endeavours too numerous to exhaustively list
(a few interesting examples include competitive chess [69], medical diagnosis [70], biometric
recognition systems [71] and battlefield target identification [72]). A final ranked list was pre-
pared via a rank-by-rank scheme, taking the Vina, Autodock, X-Score and DrugScore scores
into account.
Capillary Electrophoresis (CE)
Capillary electrophoresis (CE) is an analytical technique used to study the interaction between
biomacromolecules [73, 74]. In CE, electrophoresis is carried out in the interior of a narrow
capillary. The technique separates ions based on their electrophoretic mobility with the use of
applied voltage. The electrophoretic mobility is dependent on the charge of the molecule, the
viscosity and the molecular size. CE is performed using a high voltage to produce a high resolu-
tion profile with a short migration time to separate numerous analytes. CE possesses several
advantages over other common techniques such as Surface Plasmon Resonance (SPR), Nuclear
Magnetic Resonance (NMR) or Isothermal Calorimetry (ITC). For example, there is no protein
size limit, the protein does not need to be modified or tethered, and the technique results in lit-
tle sample consumption. The assay provides a high sensitivity through the use of a Laser
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Induced Fluorescence (LIF) detector to enable the detection of weak binding fragments. This
enables the interaction assay to be performed with a low labelled probe concentration and al-
lows compounds to be screened at low concentrations. A competitive CE assay was used to de-
tect competition between compounds and fluorescently labelled p53 peptide (p53-F) in
MDM2-N/p53 binding site. The injection sample contained carboxyfluorescein (internal stan-
dard (10pM)) and p53-F (500pM) in TAPS/Tris (1mM) pH 8.0, DTT (1mM). The separation
sample contained MDM2-N (160nM), test compound (300μM), TAPS/Tris (200mM) pH 8.0,
DMSO (1% f/c) and glycerol (0.25%). Compounds were screened at 300μM concentration as
the initial screening concentration, depending on the compound solubility. After injection of
the sample, a voltage of 10kV was applied and separation was carried out for 6.5min. The mi-
gration time of the p53-F peak was detected by laser induced fluorescence (LIF) detector and
the inhibition (%) was calculated using the equation below.
% Inhibition ¼ 100ðTH TLÞ=ðTH TRÞ
Where: TH is migration time of p53-F peak in the presence of MDM2-N.
TR is the migration time of p53-F peak.
TL is the migration time of p53-F peak in the presence of MDM2-N + compound.
Fluorescence polarization (FP) assay
Fluorescence polarization experiments were performed with a LJL Biosystems Analyst multi-
plate reader in 50mMHEPES pH 7.5, 100mMNaCl, 1mM DTT. Fluorescein labelled p53 pep-
tide (p53-F) was synthesised by Biomatiks. The excitation and emission wavelengths were set
to 490 and 525nm. The competition experiments were carried out by mixing MDM2-N
(500nM), p53-F (2nM) and test compound in black NBS plate. Compounds were screened at
700μM concentration as the initial screening concentration, depending on the compound solu-
bility. The inhibition (%) was calculated using the equation below.
% Inhibition ¼ 100ðAF ALÞ=ðAF AUÞ
Where: AF is the anisotropy of fully bound p53-F.
AU is the anisotropy of unbound p53-F.
AL is the anisotropy of p53-F in the presence of MDM2-N + compound.
Ethics Statement
No approval from any ethics committees was required as no animal, human, cell line or field
sampling experiments took place.
Results
Redocking Control Experiment
The structure of MDM2 in complex with an MI-63 analogue was used for the docking studies
(PDB 3LBL, Fig 1). Its high resolution (1.60 Å), good R-factors (R = 0.193, Rfree = 0.236) and
the small molecule ligand-binding conformation of the protein made it ideal for this purpose.
The ligand present in the structure was redocked to verify that the docking programs used for
the virtual screening were successfully able to correctly predict its binding conformation. Auto-
dock successfully reproduced the crystallographic binding mode of the ligand, the result being
within an RMSD of 0.83 Å. Vina also correctly predicted the binding pose of the ligand, with
an RMSD of 0.67 Å. Autodock predicted the free energy of binding to be -9.4 kcal/mol, Vina
predicted -9.8 kcal/mol. These are both roughly equivalent to a Ki around the 100 nMmark,
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and are remarkably close to the measured Ki of 36 nM [36]. Fig 2 shows a superposition of the
docking results with the crystal structure.
Virtual Screening Results
An initial ligand-based pharmacophore screen was carried out. A total of 23,588 compounds
were returned. Vina and then Autodock were used to dock the top hits from LIDAEUS. A sim-
ple pharmacophore filter was designed by identifying the main features of the MI-63-analog li-
gand that are involved in interactions with MDM2 (Fig 2). This resulted in a final ranked list of
2120 molecules; the predicted binding modes of the top 266 were inspected manually for final
selection. 38 of these were chosen for acquisition and assay. S2 Table lists their details. Com-
pound 16 was found to be unavailable for purchase, therefore the most similar compound in
stock was selected as a substitute (39, Fig 3)
CE binding Assay results
Racemic Nutlin-3 was used to confirm if the p53-F/MDM2-N peak shifted to its original “apo”
position in the presence of a known inhibitor. Upon adding Nutlin-3 (100nM), the peak shifted
back to the p53-F peak position with a change in peak shape indicating the competition be-
tween p53-F and Nutlin-3 in the MDM2-N binding site (Fig 4, lower trace).
With additional titration, the IC50 of Nutlin-3 could be calculated. Nutlin-3 was titrated
from 400 nM to 0.5 nM and % inhibition was calculated from the migration time of Nutlin-3
(Fig 5). The % inhibition was fitted against Nutlin-3 concentration in log scale in GraphPad
Prism and IC50 was calculated to be 37.50 nM. The calculated IC50 is similar to the literature
value for racemic Nutlin-3 of 100 nM [34]. This confirms that CE is able to recognise inhibitor
binding and able to calculate an accurate IC50.
FP assay results
The FP competition experiment was carried out to test whether the FP assay was suitable for
identifying small molecule inhibitors for MDM2-N. A dose response experiment was per-
formed using Nutlin-3 from 0.02 μM to 10 μM. MDM2-N concentration was held constant at
500 nM and p53-F was 2 nM in the mixture. The anisotropy was fitted against Nutlin-3 con-
centration in GraphPad Prism and IC50 was calculated to be 266 nM (Fig 6). Five of the virtual
screening compounds were identified to be active in both CE and FP assay (Fig 3).
Analogue exploration
These initial virtual screening hits, although active, exhibited high molecular weight and low
solubility. Therefore it was determined that smaller molecular weight fragments with higher
solubility should be identified. Analogues of the virtual screening hit 19 were further explored
because the structure was novel and different from known inhibitors. 19 was further explored
using the Selcia chemical store substructure search tool in the Selcia compound library. Com-
pounds containing a similar motif as 19 (Fig 7) were tested in the CE and FP assay.
A total of 5 of the 38 compounds acquired on the basis of the analogue exploration showed
inhibition of MDM2 in the CE assay at 300 μM (Fig 8). An additional compound was tested at
only 50 μM due to solubility issues and this also showed inhibition. Of these 6 compounds, 4
showed greater than 10% inhibition of MDM2 in the orthogonal FP assay at 700 μM (Fig 8).
The less soluble compound again could only be tested at 50 μM and showed no inhibition in
the FP assay at this concentration.
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Fig 2. Control docking results.Crystallographic pose is coloured black, intermolecular hydrogen bonds are shown as orange dashes, Autodock result is
red, Vina result is magenta. Pharmacaphore filter points are shown as black spheres. The protein is represented as a white transparent surface and cartoon
secondary structure; residue side chains within 5 Å of the ligand are shown as black lines.
doi:10.1371/journal.pone.0121424.g002
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Fig 3. Structural formulae of the 5 hits identified through the initial virtual screen.
doi:10.1371/journal.pone.0121424.g003
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Discussion
Inspection of the output from the initial ligand-based pharmacophore screen found that com-
pounds 1, 2, 16 and 19 were present in the output from the ROCS 3D similarity search.
Fig 4. Nutlin-3 titration. As the Nutlin-3 concentration increases the peak shifted back to p53-F control peak.
Top trace is the p53-F alone followed by p53-F with MDM2-N. Nutlin-3 was then added into the sample with
increasing concentration.
doi:10.1371/journal.pone.0121424.g004
Fig 5. Graph showing inhibition (%) plotted against Nutlin-3 concentration. From the data an IC50 of
37.3nM was determined.
doi:10.1371/journal.pone.0121424.g005
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Compounds 16, 19 and 24 were present in the output from the UFSRAT 3D similarity search.
Only 16 was present in the EDULISS 2D similarity search output. None of the compounds that
exhibited activity in both assays were present in the LIDAEUS rigid-body docking output.
Compounds 1, 2, 16 and 19 had been ranked most highly by the X-Score scoring algorithm,
with 24 selected by Vina’s scoring algorithm. Vina has previously been shown to perform well
in predicting the binding modes and relative affinities of MDM2 ligands [51] such as MI-63
and Telmisartan, which have been included in S2 Table for comparison. We also found that we
were able to reproduce the predicted binding modes of MI-63 and Telmisartan as described in
Patil et al. using Vina (Fig 2 and S1 Fig). In addition, the scoring algorithms chosen would have
successfully identified both of these known high-affinity actives (S2 Table).
Fig 6. Competition of Nutlin-3 with p53-F for MDM2-Nmeasured by FP assay. The graph shows
anisotropy plotted against Nutlin-3 concentration. An IC50 of 266 nM was determined.
doi:10.1371/journal.pone.0121424.g006
Fig 7. Diphenylamine fragment based on the virtual screening hit 19.
doi:10.1371/journal.pone.0121424.g007
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All of the actives contain either chiral centres in their central scaffolds or rotatable bonds
positioned such that, when adopting their predicted binding conformations, they can substan-
tially occupy all three dimensions in space. This 3D characteristic has recently been identified
as important both for MDM2 inhibitors and for protein-protein interaction inhibitors in gen-
eral [75, 76].
Compounds 1 and 2 both contain central imidazole or pyrrole groups to which three hydro-
phobic groups are attached (Fig 3). These dock into the three pockets of MDM2’s binding site,
into which the Phe, Trp and Leu side chains of p53 bind. Of the 38 compounds tested, Com-
pound 36 and Compound 38 appear structurally similar to these hits yet were inactive. Howev-
er, both of these inactive compounds are planar whereas the two active compounds possess
groups that project out from the plane of the imidazole group. The importance if this structural
feature is confirmed when these compounds are compared to the cis-imidazolidines, for exam-
ple Nutlin-3, in which both of its chlorobenzene groups project out of the plane of the mole-
cule. RG7388 and RG7112 are molecules of this class of central imidazole or pyrrole scaffold
that have very recently been identified and entered into clinical trials [77, 78]. Other pyrrole-
containing MDM2 inhibitors have also been described recently [79]. AMG 232 is a somewhat
related class of molecule from a pharmacophoric perspective, as although its central ring is a
6-membered piperidine group this still act as the nonplanar scaffold which positions the three
attached protein-interacting hydrophobic groups. It too was recently identified and has entered
clinical trials [80].
We were unable to test the isoindolinone 16 as although it was present in our virtual chemi-
cal library, which is based on the stock lists of various commercial compound suppliers, it was
unavailable for purchase at the time of enquiry. Therefore, the most similar compound avail-
able was selected instead. Compound 39 constitutes a substructure of 16 (Fig 3). On identifica-
tion of its activity in the assays a literature search revealed that this moiety has already been
found to serve well as a scaffold for the design of MDM2 inhibitors [81].
Compound 24 appears more novel, possessing little similarity with the current classes of
known MDM2 small molecule inhibitors (Fig 1 and Fig 3). Three similar compounds were in-
active, one of which differed by only one methyl group on the piperidine moiety. Compound
26 contains a 4-methylpiperidine, Compound 25 a 2,4-dimethylimidazole, and Compound
32 a cycloheptane group at this location, all of which are larger and, according to the docking
results, project deeper into the p53 Trp pocket of MDM2 (Fig 9). The docking and assay
results combined suggest a strict size limit on the length of the moiety that this pocket can
accommodate.
Compound 19 is also novel compared to known inhibitors. It was also the only compound
tested that contained a diphenylamine group. Seven of the compounds tested contain diphenyl-
methane groups, which are superficially similar, but none were active. This prompted an investi-
gation of the contribution the diphenylamine group makes to binding. Several diphenylamine-
containing fragments were tested, five of which showed inhibition in both assays (Fig 8). Dock-
ing these fragments suggests that they adopt the same binding conformation as the equivalent
group in 19 (Fig 10 and S1 Fig and S3 Table). The predicted binding mode suggests that the cen-
tral NH group does not take part in any hydrogen bonding with the protein, therefore it appears
likely that it is the difference in configuration between the secondary carbon and the amine
group (pyramidal vs. planar) that is responsible for the difference in activity. However, analysis
of additional low energy binding modes for these molecules suggests that they may adopt
Fig 8. Further exploration of analogues of virtual screening hit 19. 6 analogues selected on the basis of the hits showed inhibition in both the CE and
FP assays.
doi:10.1371/journal.pone.0121424.g008
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alternate binding positions in the pocket (S1 Fig and S3 Table). Indeed it is to be expected that
the limited number of interactions small fragments can make with a pocket bestows them with
pharmacophores of limited structural specificity and thus a propensity to promiscuity. Both in
silico studies and in vitro assay experiments confirm this [10, 82–84]. This is borne out when a
comparison of ΔG is made between Vina's top docking solutions; this indicates that larger mole-
cules tend to exhibit clearer docking solutions than fragments (S4 Table). Telmisartan appears to
be the exception to this, likely due to the relatively large number of rotatable torsions making
this compound more flexible, and multiplying the number of ways it can potentially fit the bind-
ing site. MI-63 has only four rotatable bonds, whereas Telmisartan has seven; this makes MI-63
more likely than Telmisartan to have only one way it can fit the pocket with significantly lower
energy, as reflected both in the shape of its graph in S4 Table and the consensus exhibited be-
tween consecutive Autodock docking attempts (S3 Table).
Fig 9. Lowest energy Vina (magenta) andmost populous cluster Autodock (green) docking poses of
the active compounds. The pharmacophore filter points are shown as black spheres. MDM2 is shown as a
white transparent surface representation with the backbone visible as black secondary structure. Side chains
of residues that line the active site are shown as black sticks. A) Compound 1; B) Compound 2; C) Compound
19 D) Compound 24
doi:10.1371/journal.pone.0121424.g009
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Conclusion
Although the library used for the virtual screening had been filtered according to "lead-like"
rules (because the initial aim was to identify compounds suitable for optimisation into more
drug-like molecules), subsequent investigation found that some of the compounds contained a
fragment that also inhibits MDM2. The activity against MDM2 of diphenylamine, identified
here though exploration of virtual screen hits, has not been previously identified. None of the
previously known small molecule inhibitors of MDM2 contain this group. Its relative potency
despite its small size means that it possesses good ligand efficiency, a characteristic that is high-
ly desirable in an inhibitor scaffold. As such it could form a starting point for a series of diphe-
nylamine based inhibitors that form interactions with a greater portion of MDM2’s p53
binding site, for which full binding curves to determine Kis will be necessary to perform a com-
plete SAR analysis.
The virtual screening method used to discover these novel compounds is generally applica-
ble to any target for which an atomic-resolution structure is known; therefore further inhibitor
discovery using this technique is being pursued. It was noted that the 3D ligand-based compar-
ison techniques identified the majority of the actives, not the 2D comparison or the 3D rigid-
body docking methods. In addition, only scoring by X-Score and Vina (methods which are
somewhat related [40]) brought these compounds to the top of the ranked list. However the
sample size of four actives in total is too small to draw any conclusions regarding which
computational or ranking method was superior.
Supporting Information
S1 Fig. Docking poses for the diphenylamine-based fragments; Vina (magenta) and Auto-
dock (green) are shown as sticks with polar hydrogens visible; predicted hydrogen bonds
are depicted as yellow dashed lines; a) compound 43; b) compound 45; c) compound 41; d)
compound 42; e) compound 44
(TIF)
S1 Table. Structural formulae of ligands in complex with MDM2 used for the ligand-based
virtual screening.
(DOCX)
Fig 10. A) Vina docking poses of Compound 16 (magenta) and Compound 39 (orange); B) Vina
docking poses of Compound 19 (magenta) and diphenylamine (orange).
doi:10.1371/journal.pone.0121424.g010
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S2 Table. Virtual screening statistics of compounds selected for assay. Rank scores within
the various ranking schemes are indicated, noninteger rank scores indicate positions tied be-
tween an even number of compounds; positions were determined for all compounds for which
Autodock and Vina both predicted similar binding modes; this numbered 2,120 compounds.
For those compounds found to be active, the scoring algorithm that ranked them highest is in-
dicated by highlighting in the rank position in yellow. Compounds found to exhibit activity in
both the CE and FP assays. †Compound not in stock at time of acquisition and substituted by
the similar compound 39. Results for the known inhibitors MI-63 and Telmisartan are includ-
ed for comparison.
(DOCX)
S3 Table. Summary of docking energies of fragment low energy binding modes versus con-
trols. Molecules that passed the "consensus docking" filter criteria. †Molecules for which
Autodock finds only one cluster of docking solutions—experience suggests that these tend to
be more reliable predictions of binding mode.
(DOCX)
S4 Table. Vina predicted ΔG for each of its top 9 docking solutions. Larger molecules (with
the exception of the flexible Telmisartan) tend to exhibit clearer solutions than fragments.
(DOCX)
S5 Table. Summary of the solubilities of the fragments in assay buffer.
(DOCX)
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